ADOPA
Publicado: 02/25/2023
DOI: https://doi.org/10.58994/adopa.v1i1.3
Factores pronósticos en pacientes pediátricos con síndrome inflamatorio multisistémico asociado a COVID-19
Cómo citar
Resumen
Introducción: la infección por COVID-19 puede dar indicios de cuándo podría convertirse en síndrome inflamatorio multisistémico.
Material y métodos: estudio descriptivo, observacional, de corte transversal, con el obje- tivo de analizar los factores pronósticos en pacientes pediátricos con síndrome inflamatorio multisistémico asociado a la COVID-19, Hospital Materno Infantil San Lorenzo, de Los Mina, julio-diciembre 2020.
Resultados: de 148 pacientes fueron captados 21 casos con síndrome inflamatorio multi- sistémico asociado a la COVID-19, (14.19 %). Edades comprendidas de seis meses a 16 años, los de 10-14 años con un 36.36 %. En el sexo masculino fue más prevalente con un 66.67 %. Procedentes de la zona urbana, 85.71 %. Extranjeros, 14.29 %. Antecedentes personales pato- lógicos: asma, diabetes mellitus tipo I, neumonía, mixtos de asma más tuberculosis; asma más neumonía, asma más diabetes, se tomó en cuenta antecedentes no patológico de consumo de sustancia tóxicas, el 9.52 % manifestó consumir hookah. Las manifestaciones clínicas principales en orden de frecuencia fueron fiebre, rash cutáneo, dificultad respiratoria, equi- mosis, petequias, tos y hematomas, evacuaciones líquidas y palidez y púrpura. Se tomaron en cuenta los laboratorios: Dimero-D, así como la ferritina, procalcitonina, proteína C reactiva y velocidad de sedimentación eritrocitaria, siendo elevado en todos los casos. La proporción de pacientes que fueron con traslado coordinado fueron 52.38 %; pacientes no coordinados desde otros centros de salud 19.05 %. Con relación a la condición de egreso la entidad cursa con una alta mortalidad.
Conclusiones: las manifestaciones clínicas se presentan como factores pronósticos, la edad, el sexo y los resultados de laboratorio nos indican valorar e identificar el SIM-COVID19, alertando además el riego de mortalidad.
Abstract
Introduction: The COVID-19 infection can give indications of when it could become a multisystem inflammatory syndrome.
Material and methods: Descriptive, observational, cross-sectional study with the aim of analyzing prognostic factors in pediatric patients with multisystem inflammatory syndrome associated with COVID-19, Hospital Materno Infantil San Lorenzo, de Los Mina, July-De- cember 2020.
Results: Of 148 patients, 21 cases with multisystem inflammatory syndrome associated with COVID-19 were captured (14.19%). Ages from six months to 16 years, those of 10-14 years with 36.36%. In the male sex it was more prevalent with 66.67%. 85.71% from the urban area. Foreig- ners’ 14.29%. Personal medical history asthma, type I diabetes mellitus, pneumonia, mixed asthma plus tuberculosis; asthma plus pneumonia, asthma plus diabetes, non-pathological history of toxic substance consumption was considered, 9.52% reported consuming hookah. The main clinical manifestations in order of frequency fever, skin rash; respiratory distress, ecchymosis, petechiae, cough and bruising, liquid stools, and pallor and purpura. The labo- ratories were considered: D-dimer, as well as ferritin, procalcitonin, reactivated protein and erythrocyte sedimentation rate, being high in all cases. The proportion of patients who went with coordinated transfer was 52.38%; uncoordinated patients from other health centers 19.05%. In relation to the discharge condition, the entity has a high mortality.
Conclusions: Clinical manifestations are presented as prognostic factors, age, sex, and laboratory results indicate us to assess and identify SIM-COVID19, also alerting the risk of mortality.
Palabras Claves
Keywords
Referencias
Meehan MT, Rojas DP, Adekunle AI, Adegboye OA, Caldwell JM, Turek E, Williams BM, Marais BJ, Trauer JM, McBryde ES. Modelling insights into the COVID-19 pandemic. Paediatr Respir Rev. 2020;35:64-9. doi: 10.1016/j.prrv. 2020.06.014.
Khan M, Khan H, Khan S, Nawaz M. Epidemiological and clinical charac- teristics of coronavirus disease (COVID-19) cases at a screening clinic during the early outbreak period: a single-centre study. J Med Microbiol. 2020;69(8):1114-23.
Martos Pérez F, Luque Del Pino J, Jiménez García N, Mora Ruiz E, Asencio Méndez C, García Jiménez JM, Navarro Romero F, Núñez Rodríguez MV. Comorbidity and prognostic factors on admission in a COVID-19 cohort of a general hospital. Rev Clin Esp. 2020;S0014-2565(20):30179-X. English, Spanish.
Panigrahy N, Policarpio J, Ramanathan R. Multisystem inflammatory syndrome in children and SARS-CoV-2: A scoping review. J PediatrRehabil Med. 2020;13(3):301-16. doi: 10.3233/PRM-200794.
Maestre-Muñiz MM, Arias Á, Arias-González L, Angulo-Lara B, Lucendo AJ. Prognostic Factors at Admission for In-Hospital Mortality from COVID-19 Infection in an Older Rural Population in Central Spain. J Clin Med. 2021;10(2):318.
Pavlyshyn H, Slyva V, Dyvonyak O, Horishna I. Multisystem inflammatory syndrome in children (MIS-C) temporally associated with SARS-CoV-2: the first clinical case in Ternopil, Ukraine. Germs. 2021;11(1):120-7. doi: 10.18683/ germs.2021.1249.
Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020;383(4):334-46. doi: 10.1056/NEJMoa2021680.
Kaushik A, Gupta S, Sood M, Sharma S, Verma S. A Systematic Review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 Infection. Pediatr Infect Dis J. 2020;39(11):e340-e346.
García-Salido A, de Carlos Vicente JC, BeldaHofheinz S, Balcells Ramírez J, Slöcker Barrio M, Leóz Gordillo I, et al. Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain. Crit Care. 2020;24(1):666.
Panigrahy N, Policarpio J, Ramanathan R. Multisystem inflammatory syndrome in children and SARS-CoV-2: A scoping review. J PediatrRehabil Med. 2020;13(3):301-16. doi: 10.3233/PRM-200794. Erratum in: J PediatrRehabil Med. 2021;14(1):137.
Goldman RD. Coronavirus disease 2019 in children: Surprising findings in the midst of a global pandemic. Can Fam Physician. 2020;66(5):332-4.
Deza Leon MP, Redzepi A, McGrath E, Abdel-Haq N, Shawaqfeh A, Sethu- raman U, Tilford B, Chopra T, Arora H, Ang J, Asmar B. COVID-19-Associated Pediatric Multisystem Inflammatory Syndrome. J Pediatric Infect Dis Soc. 2020;9(3):407-8.
Pereira MFB, Litvinov N, Farhat SCL, Eisencraft AP, Gibelli MABC, Carvalho WB, et al. Severe clinical spectrum with high mortality in pediatric patients with COVID-19 and multisystem inflammatory syndrome. Clinics (Sao Paulo). 2020;75:e2209.
Duarte Mote J, Espinosa López R, Sánchez Rojas G, De Santiago Leaños J, Díaz Meza S, Eng Castro E. Síndrome de respuesta inflamatoria sisté- mica. Aspectos fisiopatológicos. RevAsoc Mex MedCrit y Ter Int, 2009;23 (4):225-33
Kaukonen KM, Bailey M, Pilcher D, Cooper DJ, Bellomo R. Systemic inflam- matory response syndrome criteria in defining severe sepsis. N Engl J Med. 2015;372(17):1629-38. doi: 10.1056/NEJMoa1415236.
Balk RA. Systemic inflammatory response syndrome (SIRS): where did it come from and is it still relevant today? Virulence. 2014;5(1):20-6. doi: 10.4161/ viru.27135.
Williams JM, Greenslade JH, McKenzie JV, Chu K, Brown AFT, Lipman J. Systemic Inflammatory Response Syndrome, Quick Sequential Organ Func- tion Assessment, and Organ Dysfunction: Insights from a Prospective Data- base of ED Patients With Infection. Chest. 2017;151(3):586-96.
Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ, The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine Definitions for sepsis and organ failure and guidelines for the use of innovative thera- pies in sepsis. Chest. 1992;101:1644–55.
Balk RA. Severe sepsis and septic shock. Definitions, epidemiology, and clinical manifestations. Crit Care Clin. 2000;16:179–92. doi: 10.1016/S0749- 0704(05)70106-8.
Bone RC. The pathogenesis of sepsis. Ann Intern Med. 1991;115:457–69. doi: 10.7326/0003-4819-115-6-457
Balk RA, Bone RC. The septic syndrome. Definition and clinical implications. Crit Care Clin. 1989;5:1–8.
Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med. 1997;25:1095–100.
Agha R, Kojaoghlanian T, Avner JR. Initial Observations of COVID-19 in US Children. Hosp Pediatr. 2020;10(10):902-5.
De Luca CD, Esposito E, Cristiani L, Mancino E, Nenna R, Cortis E, Midulla F. COVID-19 in children: A brief overview after three months experience. Paediatr Respir Rev. 2020;35:9-14.
Balasubramanian S, Rao NM, Goenka A, Roderick M, Ramanan AV. Corona- virus Disease 2019 (COVID-19) in Children - What We Know So Far and What We Do Not. Indian Pediatr. 2020;57(5):435-42.
Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, Klein JD, Bhutta ZA. COVID-19 and multisystem inflammatory syndrome in children and adoles- cents. Lancet Infect Dis. 2020 Nov;20(11):e276-e288.
Sood M, Sharma S, Sood I, Sharma K, Kaushik A. Emerging Evidence on Multisystem Inflammatory Syndrome in Children Associated with SARS-CoV-2 Infection: a Systematic Review with Meta-analysis. SN Compr Clin Med. 2021;3: 1-10. doi: 10.1007/s42399-020-00690-6.
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysio- logy, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;324(8):782-93.
Heyland DK, Dhaliwal R, Day AG et al. Reducing deaths due to oxidative stress (The REDOXS Study): Rationale and study design for a randomized trial of glutamine and antioxidant supplementation in critically-ill patients. Proc Nutr Soc 2006;65:250-63.
Ye ZW, Jin DY. [Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future]. Sheng Wu Gong Cheng Xue Bao. 2020;36(4):571-92. doi: 10.13345/j.cjb.200115. PMID: 32347053.
Nakra NA, Blumberg DA, Herrera-Guerra A, Lakshminrusimha S. Multi- System Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Review of Clinical Presentation, Hypothetical Pathogenesis, and Proposed Management. Children (Basel). 2020;7(7):69. doi: 10.3390/chil- dren7070069.
Esposito S, Principi N. Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2. Paediatr Drugs. 2021;23(2):1–11. doi: 10.1007/s40272- 020-00435-x.
World Health Organization. WHO characterizes COVID-19 as a pandemic. 1.1.[2020-03-12]. https://www.who.int/emergencies/diseases/novel-coro-navirus-2019/events-as-they-happen.
Matthew C. Wong, Sara J. JavornikCregeen, Nadim J. Ajami, et al. Evidence of recombination in coronaviruses implicating pangolin origins of 2019-nCoV [J]. BioRxiv, 2020.
Qiang Zhou, Renhong Yan, Yuanyuan Zhang, et al. Structure of dimeric full- length human ACE2 in complex with B0ATI [J]. BioRxiv, 2020.
Menter T, Haslbauer JD, Nienhold R, Savic S, Hopfer H, Deigendesch N, et al. Examen post mortem de los pacientes con COVID-19 revela daño alveolar difuso con congestión capilar grave y hallazgos variados en los pulmones y otros órganos que sugieren disfunción vascular. Histopatología. 2020;77(2): 198-209.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Características clínicas de los pacientes infectados con el nuevo coronavirus de 2019 en Wuhan, China. Lanceta, 2020;395(10223):497-506.
Tran Thi, Nhu Thao, Fabien Labroussaa, Nadine Ebert, et al. Rapid reconstruc- tion of SARS-CoV-2 using a synthetic genomics platform [J]. Bio Rxiv, 2020.
Xiaolu Tang, Changcheng Wu, Xiang Li, et al. On the origin and continuing evolution of SARS-CoV-2 [J]. National Science Review, nwaa036. https://doi.org/10.1093/nsr/nwaa036.
Licencia
